Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2021

01-09-2021 | Myelodysplastic Syndrome | short review

New trends in autologous and allogeneic stem cell transplantation—an update from the annual ASH meeting 2020

Authors: PD Dr. Alexandra Böhm, Prof. Dr. Felix Keil

Published in: memo - Magazine of European Medical Oncology | Issue 3/2021

Login to get access

Summary

At the 62nd annual meeting of the American Society of Hematology (ASH) 2020—which took place virtually for the first time—numerous clinical studies and research results were presented. The latest trends and exciting developments in the field of stem cell transplantation can be found in the following article, e. g. how transplantations with a mismatch donor can be safely performed, important studies regarding MDS and ALL patients, a promising second-line treatment in chronic GVHD, why the nutritional status and the microbiome should be part of the pre-transplant work-up and that lifelong follow-up for children and young adolescents after an allogeneic transplantation is essential.
Literature
1.
Shaw BE, Jimenez-Jimenez A, Burns LJ, et al. Bridging the gap in access to transplant for Underserved minority patients using mismatched unrelated donors and post-transplant cyclophosphamide: a national marrow donor program/be the match (NMDP/BTM) initiative. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 297.
2.
Nakamura R, Saber W, Martens MJ, et al. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50–75 with advanced myelodysplastic syndrome: blood and marrow transplant clinical trials network study 1102. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 75.
3.
Giebel S, Labopin M, Houhou M, et al. Comparison of reduced intensity conditioning—allogeneic HCT and autologous HCT for elderly patients with acute lymphoblastic leukemia. An analysis from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 614.
4.
Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 77.
5.
Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 143.
6.
Tucci A, Re A, Pagani C, et al. Rituximab with dose-adjusted EPOCH (R-DA-EPOCH) with or without autologous stem cell transplantation (ASCT) as first line treatment in patients with aggressive B‑cell lymphoma with MYC and BCL‑2 and/or BCL‑6 gene rearrangements or increase copy number. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2131.
7.
Brauer D, Backhaus D, Vucinic V, et al. Prognostic impact of nutritional status at diagnosis and weight changes in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2431.
8.
Sallfors Holmqvist A, Chen Y, Wu J, et al. Severe/life-threatening/fatal chronic health conditions (CHcs) after allogeneic blood or marrow transplantation (BMT) in childhood—a report from the BMT survivor study (BMTSS). 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 69.
Metadata
Title
New trends in autologous and allogeneic stem cell transplantation—an update from the annual ASH meeting 2020
Authors
PD Dr. Alexandra Böhm
Prof. Dr. Felix Keil
Publication date
01-09-2021
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2021
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00725-1

Other articles of this Issue 3/2021

memo - Magazine of European Medical Oncology 3/2021 Go to the issue

case report

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis

short review

Clinically relevant infections in hematology and oncology: bacterial infections and the role of novel antibiotics in times of multidrug resistance

editorial

Clinically relevant infections in hematatology and oncology

short review

Top 3 abstracts concerning hormone-receptor-positive early breast cancer

short review

Post San Antonio update—my top three abstracts!

case report

Primary diffuse leptomeningeal melanomatosis: report of three pediatric cases and review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits